These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17541273)

  • 1. Mechanism for the differentiation of EoL-1 cells into eosinophils by histone deacetylase inhibitors.
    Kaneko M; Ishihara K; Takahashi A; Hong J; Hirasawa N; Zee O; Ohuchi K
    Int Arch Allergy Immunol; 2007; 143 Suppl 1():28-32. PubMed ID: 17541273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism for the decrease in the FIP1L1-PDGFRalpha protein level in EoL-1 cells by histone deacetylase inhibitors.
    Ishihara K; Kaneko M; Kitamura H; Takahashi A; Hong JJ; Seyama T; Iida K; Wada H; Hirasawa N; Ohuchi K
    Int Arch Allergy Immunol; 2008; 146 Suppl 1():7-10. PubMed ID: 18504399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of eosinophilic leukemia EoL-1 cells into eosinophils induced by histone deacetylase inhibitors.
    Ishihara K; Takahashi A; Kaneko M; Sugeno H; Hirasawa N; Hong J; Zee O; Ohuchi K
    Life Sci; 2007 Mar; 80(13):1213-20. PubMed ID: 17258775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms for the proliferation of eosinophilic leukemia cells by FIP1L1-PDGFRalpha.
    Ishihara K; Kitamura H; Hiraizumi K; Kaneko M; Takahashi A; Zee O; Seyama T; Hong J; Ohuchi K; Hirasawa N
    Biochem Biophys Res Commun; 2008 Feb; 366(4):1007-11. PubMed ID: 18086564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible mechanism of action of the histone deacetylase inhibitors for the induction of differentiation of HL-60 clone 15 cells into eosinophils.
    Ishihara K; Hong J; Zee O; Ohuchi K
    Br J Pharmacol; 2004 Jul; 142(6):1020-30. PubMed ID: 15210580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation.
    Buitenhuis M; Verhagen LP; Cools J; Coffer PJ
    Cancer Res; 2007 Apr; 67(8):3759-66. PubMed ID: 17440089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.
    Sadovnik I; Lierman E; Peter B; Herrmann H; Suppan V; Stefanzl G; Haas O; Lion T; Pickl W; Cools J; Vandenberghe P; Valent P
    Exp Hematol; 2014 Apr; 42(4):282-293.e4. PubMed ID: 24407160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eosinophil cell lines.
    Ishihara K
    Methods Mol Biol; 2014; 1178():45-51. PubMed ID: 24986606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of JAK2 as a mediator of FIP1L1-PDGFRA-induced eosinophil growth and function in CEL.
    Li B; Zhang G; Li C; He D; Li X; Zhang C; Tang F; Deng X; Lu J; Tang Y; Li R; Chen Z; Duan C
    PLoS One; 2012; 7(4):e34912. PubMed ID: 22523564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha.
    Baumgartner C; Gleixner KV; Peter B; Ferenc V; Gruze A; Remsing Rix LL; Bennett KL; Samorapoompichit P; Lee FY; Pickl WF; Esterbauer H; Sillaber C; Superti-Furga G; Valent P
    Exp Hematol; 2008 Oct; 36(10):1244-53. PubMed ID: 18619723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.
    Cools J; Quentmeier H; Huntly BJ; Marynen P; Griffin JD; Drexler HG; Gilliland DG
    Blood; 2004 Apr; 103(7):2802-5. PubMed ID: 14630792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib.
    Lierman E; Michaux L; Beullens E; Pierre P; Marynen P; Cools J; Vandenberghe P
    Leukemia; 2009 May; 23(5):845-51. PubMed ID: 19212337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus.
    Burgstaller S; Kreil S; Waghorn K; Metzgeroth G; Preudhomme C; Zoi K; White H; Cilloni D; Zoi C; Brito-Babapulle F; Walz C; Reiter A; Cross NC
    Leukemia; 2007 Dec; 21(12):2428-32. PubMed ID: 17914408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells.
    Fukushima K; Matsumura I; Ezoe S; Tokunaga M; Yasumi M; Satoh Y; Shibayama H; Tanaka H; Iwama A; Kanakura Y
    J Biol Chem; 2009 Mar; 284(12):7719-32. PubMed ID: 19147501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Identification of FIP1L1-PDGFRA fusion, and expression of signal transducer and activator of transcription 5 in hypereosinophilic syndrome].
    Zhang GS; Li B; Pei MF; Dai CW; Zheng WL; Shen JK
    Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(18):1541-4. PubMed ID: 15500716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia.
    Cools J; Stover EH; Wlodarska I; Marynen P; Gilliland DG
    Curr Opin Hematol; 2004 Jan; 11(1):51-7. PubMed ID: 14676627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triptolide abrogates oncogene FIP1L1-PDGFRalpha addiction and induces apoptosis in hypereosinophilic syndrome.
    Jin Y; Chen Q; Lu Z; Chen B; Pan J
    Cancer Sci; 2009 Nov; 100(11):2210-7. PubMed ID: 19671059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin.
    Jin Y; Ding K; Li H; Xue M; Shi X; Wang C; Pan J
    Mol Cancer; 2014 Jan; 13():17. PubMed ID: 24472312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncostatin M is a FIP1L1/PDGFRA-dependent mediator of cytokine production in chronic eosinophilic leukemia.
    Hoermann G; Cerny-Reiterer S; Sadovnik I; Müllauer L; Bilban M; Gröger M; Horny HP; Reiter A; Schmitt-Graeff A; Mannhalter C; Valent P; Mayerhofer M
    Allergy; 2013 Jun; 68(6):713-23. PubMed ID: 23621172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
    Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
    Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.